This page contains recent news articles, when available, and an overview of Myelofibrosis but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

News: Myelofibrosis

PR Newswire (press release)..."The utility of JAK2 inhibitors may be broadly applicable and is not limited to myelofibrosis. Additional potential indications include other MPNs, ...

Incyte 3Q loss narrows on lower costs  -  ‎Nov 5, 2009‎
The Associated Press...which we intend to use to complete the Phase III program for our lead JAK1/2 inhibitor, INCB18424, for myelofibrosis, advance our pipeline, ...

Incyte Corporation Q3 2009 Earnings Call Transcript  -  ‎Nov 5, 2009‎
Seeking Alpha (blog)Does that imply that the oncology rights to utilize [inaudible] in the US Is that only specific in myelofibrosis or it depends on the cancer types? ...

Air Station Marine donates kidney to save SC teen  -  ‎Nov 11, 2009‎
Hilton Head Island PacketThose medications were needed to treat the aftereffects of myelofibrosis, a rare disease that disrupts the body's ability to develop red blood cells. ...

Marine donates kidney to 15-year-old  -  ‎Nov 15, 2009‎
Charleston Post CourierThose medications were needed to treat myelofibrosis, a rare disease that disrupts the body's ability to develop red blood cells. ...

Incyte Beats Estimates Marginally  -  ‎Nov 9, 2009‎
Zacks.comThe oral formulation of the compound is undergoing phase III trials for the treatment of myelofibrosis, Polycythemia Vera and Essential Thrombocythemia. ...

Working with poultry linked to certain cancers  -  ‎Nov 2, 2009‎
Reuters9 times higher-for several forms of the disease, including cancer of the tonsils, nasal cavity and sinuses, and a blood cancer called myelofibrosis. ...

Kippenslachters hebben eerder kans op kanker  -  ‎Nov 5, 2009‎
Meat & MealDit aantal was op zich niet hoger dan gemiddeld, maar het aantal mensen dat aan keelkanker, bloedkanker (myelofibrosis) en voorhoofdsholtekanker overleden, ...

* Reaches SPA agreement with FDA on myelofibrosis drug  -  ‎Jul 21, 2009‎
ReutersMyelofibrosis is a disorder in which the bone marrow develops scar tissue and causes swelling of the liver and spleen. The main goal of the trial,

Incyte Corporation Q2 2009 Earnings Call Transcript  -  ‎Jul 30, 2009‎
Seeking AlphaCOMFORT-I is expected to enroll 240 patients with other primary myelofibrosis post-polycythemia vera MF or post-essential thrombocythemia MF using

Incyte Reports Second Quarter 2009 Financial Results and Provides ...  -  ‎Jul 30, 2009‎
Genetic Engineering News (press release)Agreement reached with the US Food and Drug Administration (FDA) for a Special Protocol Assessment (SPA) for INCB18424 as a treatment in myelofibrosis (MF).

Incyte Reaches Agreement with FDA on a Special Protocol Assessment  -  ‎Jul 25, 2009‎
Trading Markets (press release)COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment), is a double-blind, placebo-controlled Phase III trial comparing the efficacy www.Xtremepicks.Com: Xtremepicks Alerts For ...  -  ‎Jul 22, 2009‎
Trading Markets (press release)Incyte's most advanced compound, INCB18424, is in Phase III development for myelofibrosis. For additional information on Incyte, visit the Company's website

BiomedReports: News and FDA Updates for Thermo Fisher (NYSE:TMO ...  -  ‎Jul 22, 2009‎
Trading Markets (press release) patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF).

Morning Movers 7/21: JDAS, PKG, INCY, LAB, LXRX, CGEN Higher; RF ...  -  ‎Jul 21, 2009‎ (subscription)INCB18424, in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

The million-to-one man  -  ‎Jul 30, 2009‎
Isle of Wight County PressVic Clark, 60, of Chichester Walk, Newport, was diagnosed with acute myelofibrosis on New Year's Eve. Doctors have told Mr Clark, who has an extremely rare

Excellent Practise for Pharmaceutical Winners: BCRX, JAZZ  -  ‎Jul 21, 2009‎
TransWorldNews (press release)...reached an agreement with the US Food and Drug Administration on the design of a late-stage trial on its lead candidate, a myelofibrosis treatment.

US HOT STOCKS: Starbucks, AMD, Yahoo Active In Late Trading  -  ‎Jul 21, 2009‎
Wall Street reached an agreement with the US Food and Drug Administration on the design of a late-stage trial on its lead candidate, a myelofibrosis treatment.

Small Cap Stocks JDA Software (JDAS), Hutchinson Technology (HTCH ...  -  ‎Jul 21, 2009‎
Small Cap NetworkMyelofibrosis is a bone marrow disease. The agreement between Incyte and the FDA is called a special protocol assessment, and details how a clinical trial

Early Market Movers: Packaging Corp, Zions Bancorp  -  ‎Jul 21, 2009‎
FOXBusinessINCB18424 is designed to treat a number of myelofibrosis conditions. The stock was up 11.5% in pre-market trading. Idenix released second-quarter earnings

CSL ready to start human swine flu vax trial; Archemix and Dicerna ...  -  ‎Jul 21, 2009‎
FierceBiotechStory > Incyte has reached a Special Protocol Assessment deal on the design of its late-stage trial of a new therapy for myelofibrosis.

JDAS, INCY, LUV, CIT, USPH, KCI, EXC, NRG, CAL Popular Stocks  -  ‎Jul 21, 2009‎
Ub reached an agreement with the US Food and Drug Administration on the design of a late-stage trial on its lead candidate, a myelofibrosis treatment.

Registry a life-saver  -  ‎Jul 20, 2009‎
Toronto SunThe 46-year-old Toronto software programmer was diagnosed in February with the blood disease myelofibrosis, which attacks two in a million people.

Incyte与FDA达�?SPA�??定  -  ‎Jul 21, 2009‎
凤凰网...(INCY) 3.99 : Incyte宣布与美国FDA就JAK1/JAK2抑制剂myelofibrosis第三阶段实验设计的特别�??议评估(SPA)达�?�??议,治疗�?�原�?�性血�?�?�纤维化,SPA所�??供第三阶段研究

Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates ...  -  Dec 6, 2008
WELT ONLINE,There are currently no approved treatments for patients with myelofibrosis. Srdan Verstovsek, MD, Ph.D., Associate Professor, Leukemia Department,

Exelixis Reports Phase 1 Data for XL019 at ASH Annual Meeting  -  Dec 7, 2008
WELT ONLINE,The reported data are from a phase 1 trial of XL019 in patients with advanced primary myelofibrosis, or with advanced myelofibrosis occurring

Incyte To Present Updated Results From Ongoing Phase II Trial of ...  -  Dec 6, 2008
RTT News,Study INCB18424-251 is an ongoing Phase II trial in patients with primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential

Exelixis Reveals New Phase I Data Of XL019 Demonstrating Evidence ...  -  Dec 7, 2008
RTT News,The phase I dose-escalation trial enrolled a total of 30 patients with advanced primary myelofibrosis, or with advanced myelofibrosis occurring

Incyte reports promising results for drug that treats bone marrow ...  -  Dec 7, 2008
Delaware Business Ledger,There are currently no approved treatments for patients with myelofibrosis. You must be a Registered User to view the rest of the story.

Promising Results from Two Trials Highlighting Developmenttal Oral ...  -  Dec 10, 2008
WELT ONLINE,The second Phase II trial, evaluating 84 patients with advanced myelofibrosis with myeloid metaplasia, was a four-arm blinded adaptive design trial.

Research and Markets: A Competitor Analysis for Janus Kinase (JAK ...  -  Dec 10, 2008
MarketWatchThe most advanced JAK2 inhibitors are also being evaluated in phase II trials for myelofibrosis, polycythemia vera and essential thrombocythemia.

Promising New Drug Blocks Mutation In Bone Marrow Cancers  -  Dec 9, 2008
Science Daily (press release)The "big three" MPDs include polycythemia vera, essential thrombocythemia and primary myelofibrosis. Until now there have been no FDA-approved targeted

S*BIO Enters Research Collaboration with Tan Tock Seng Hospital ...  -  Dec 18, 2008
MarketWatchThe V617F mutation is found in high frequencies in various myeloproliferative disorders such as idiopathic myelofibrosis. SB1518 might also provide an

Form 4 Oracle: Boston, MA -- Form4Oracle: Insider Trading Report ...  -  Dec 22, 2008
Trading Markets (press release),The company?s products include INCB18424 (Oral), which is in Phase IIa clinical trials for the treatment of myelofibrosis, rheumatoid arthritis,

S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial ...  -  Dec 2, 2008 (press release),...a potent and orally-active JAK2 inhibitor, in leading medical centers in Australia for patients with chronic idiopathic myelofibrosis (CIMF).

Experimental Drug Fights Bone Marrow Cancers  -  Dec 9, 2008
Washington Post,...and Drug Administration-approved targeted treatments for the "big three" MPDs -- polycythemia vera, essential thrombocythemia and primary myelofibrosis.

Nplate Increased, Sustained Platelet Counts In Adult Chronic ITP ...  -  Dec 9, 2008,Bone marrow reticulin was present or increased in eight patients with no evidence of progression to collagen fibrosis or chronic idiopathic myelofibrosis.

ASH Not Earth Shattering, but Data Show Plenty of Progress  -  Dec 15, 2008
TMCnetIn the myelofibrosis field, Stanford Group Co. Analyst Han Li wrote in a research note that Incyte Corp.'s INCB424 is "well ahead of competing JAK2

ASH Wrap Up: Alphabet Soup and Drugs  -  Dec 11, 2008
Motley FoolIncyte and Motley Fool Rule Breakers pick Exelixis (Nasdaq: EXEL) are both developing Janus kinase (JAK) inhibitors for treatment of myelofibrosis (MF), Stock Trade Newsletter Reports about its Alert ...  -  Dec 10, 2008
Trading Markets (press release),...has shown promising activity with manageable safety and tolerability for the treatment of relapsed/refractory multiple myeloma (MM) and myelofibrosis.

Pharmamar Presents New Results of Aplidin(R) At The 50th ASH ...  -  Dec 10, 2008 (press release),PharmaMar has also presented the results of Aplidin® in two phase II trials and a study of the compound in animal models of myelofibrosis at ASH Annual

Incyte Reports Progress in Multiple Clinical Programs Announces ...  -  Nov 6, 2008
Business Wire (press release),On September 5, the US Food and Drug Administration (FDA) granted orphan drug designation for INCB18424 for the treatment of patients with myelofibrosis.

128 Abstracts Evaluating Celgene Products to Be Presented at the ...  -  Nov 11, 2008

Local Brief Nov. 4  -  Nov 3, 2008
Portales News-Tribune,Gardels is a cancer survivor, having undergone treatment for primary myelofibrosis, which included a bone marrow transplant in 2003.

Walk raises $11000 for charity  -  Oct 23, 2008
Las Vegas Sun,Among them was myelofibrosis (blood disease) survivor Lori Roques of Henderson. Diagnosed in 2002, she received a bone marrow transplant a year later from

Nancy Ripley Rost, devoted mom and doctor, dies at 78  -  Nov 14, 2008
Newsday,Rost died Oct. 25 at her home after suffering from myelofibrosis, a bone marrow disorder. She was 78. Born on Staten Island, where she spent her childhood,

BioLife Solutions to Supply CryoStor(TM) to Cryobanks ...  -  Nov 4, 2008
MarketWatch...stem cells that have been transfused in thousands of patients to cure numerous fatal diseases including leukemia, lymphoma, anemia, and myelofibrosis.

A call to service: Local nurse helping veterans recover  -  Nov 11, 2008
Gloucester Daily Times,The MRI detected symptoms of myelofibrosis, a bone marrow disorder that disrupts the normal production of blood cells. Without the resulting diagnosis and

George W. Nichols, 72  -  Nov 10, 2008
Faribault County Register,4, 2008, at his home after battling a rare blood disease called Myelofibrosis. George has generously donated his body to Mayo Clinic.

Celgene Corp. Q3 2008 Earnings Conference Call Transcript  -  Oct 23, 2008
Seeking Alpha,...our proprietary IMiD compound franchise, including Pomalidomide which is demonstrating activity in multiple myeloma and potential myelofibrosis.

Incyte's JAK Inhibitor Demonstrates Rapid and Marked Clinical ...  -  Oct 26, 2008
Earthtimes (press release),...(as a topical treatment), myelofibrosis, polycythemia vera, essential thrombocythemia, multiple myeloma, and hormone refractory prostate cancer.

Form 4 Oracle: Boston, MA -- Form4Oracle: Insider Trading Report ...  -  Nov 3, 2008
Trading Markets (press release),Its product portfolio also comprises XL019 that specifically inhibits the JAK2 tyrosine kinase and is being developed for the treatment of myelofibrosis,

Les mutations de JAK2 dans les syndromes myéloprolifératifs en 2008  -  Nov 12, 2008
Hématologie,Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and

Veteran waited almost 18 hours for hospital treatment  -  Jul 10, 2008
The West Australian,Helen Webster said her husband Ted Webster was told to go to hospital by his GP for treatment for a bone marrow disorder called myelofibrosis.

Dog owners battle volunteer at Middle Island dog park  -  Jul 10, 2008
Newsday,Lederman said he cares about the park's future because he has been diagnosed with terminal myelofibrosis, a disease in which fibrous tissue replaces bone

Blind war vet, 80, waits 17 hours for bed  -  Jul 9, 2008
WA today,She said Mr Webster, who suffers a Leukaemia-like blood disorder called myelofibrosis, arrived at the hospital at 5pm yesterday after complaining of muscle

Romiplostim Data Show Potential Long-Term Efficacy and Safety in ...  -  Jun 15, 2008
Netherlands Corporate News (persbericht),Bone marrow reticulin was reported in samples from eight patients with no evidence of collagen fibrosis or chronic idiopathic myelofibrosis.

Flynn has eyes on Ironman  -  Jul 3, 2008
Weekly Calistogan,Leffler was diagnosed with myelofibrosis, a rare blood disease, in 2004. He had a stem cell transplant — which he received from his sister in January 2005

Fundraiser raises $10K for Vilonia man  -  Jun 17, 2008
Log Cabin Democrat,Roberts has been diagnosed with idiopathic myelofibrosis. A chronic disease, Roberts began experimental treatment this week at the University of Texas,

Incyte's JAK Inhibitor Demonstrates Marked Clinical Benefits in ...  -  Jun 13, 2008
Centre Daily Times,...psoriasis (as a topical treatment), myelofibrosis, polycythemia vera essential thrombocythemia, multiple myeloma, and hormone refractory prostate cancer

Background information on Myelofibrosis [When available]

Myelofibrosis is the gradual replacement of the bone marrow by connective tissue. Its main feature is "extramedullary hematopoeisis", i.e. the blood-forming cells migrate to other sites in the body, e.g. the liver or spleen. Typically affects patients > 50 years. Patients will typically have hepatosplenomegaly, and the blood smear will show "teardrop cells".

Search the web for more resources on Myelofibrosis

Health Home | Conditions | Cancer | Medications | Surgery | Vaccines

The Cancer News Network


Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on lead to other sites. does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is responsible for dead or misdirected links.

We will do our best to accommodate your request.